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Until recently the treatment of carcinoma of the
prostate was limited either to radical prostatectomy
by the perinea! or retropubic route, or to hormonal
manipulation. Approximately 5% of all patients with
this disease are suitable candidates for radical surgery. Hormonal manipulation is palliative in nature
and is generally used when there is evidence of metastatic disease (in about 50% of patients). There thus
remains a group of patients (40% to 45%) in whom
the disease is localized, yet too extensive for surgical
treatment, for whom definitive radiotherapy can play
a major role.
Pre-treatment Evaluation
Once the histological diagnosis of carcinoma of
the prostate has been made it is desirable to delineate
the exact extent of disease in order to provide certain
guidelines for optimal management and for predicting prognosis. In an attempt to evaluate the various
diagnostic procedures, we at the Medical College of
Virginia are conducting an ongoing study where all
patients with clinically localized prostatic carcinoma
undergo the following work-up:
1. Laboratory Studies
a) WBC, hematocrit, platelets
b) Total and prostatic fraction of acid phosphatase (blood is obtained either prior to
or at least 24 hours after rectal examination).
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c) Alkaline phosphatase and BUN.
d) Bone marrow biopsy for histological examination, and radioimmunoassay for
prostatic acid phosphatase.
2. Radiological Studies
a) Chest x-ray
b) Intravenous pyelography
c) Bipedal lymphangiogram
d) 99 m Tc Labeled di-phosphate bone scan
Radiation Therapy
Although the use of ionizing radiation in the
treatment of carcinoma of the prostate was first reported in 1911 by Pasteau, 1 the majority of reports
have appeared within the last ten years. In a recent
comprehensive review of the subject Ray and his
colleagues 2 have documented clinical studies which
collectively report on 880 cases in which external
beam irradiation was the primary mode of treatment.
They have concluded "that potentially tumoricidal
dosage of irradiation can be delivered to the prostate
with relative safety and in general the initial response
of the local tumor to irradiation in survival rates at
five years were encouraging."
Results

Local. In general , the reports of various authors
support our experience that 70% to 80% of patients
show marked resolution of the disease within six
months on clinical examination. We do not, at the
present, recommend post-treatment prostatic
biopsies as a routine procedure.
MCV QUARTERLY 14(2): 88-89, 1978

HAZRA: RADIOTHERAPY FOR PROSTATIC ADENOCARCINOMA

Survival. On reviewing the results of various investigators dealing with the definitive treatment of
adenocarcinoma of the prostate with megavoltage
irradiation therapy, one finds that the five-year survival rate varies from 60% to 70% and the ten-year
survival rate varies from 30% to 40%. Ray and his
colleaguess from Stanford University have reported
the results of treatment for two clinical groups of
patients based upon the extent of the disease as determined by digital examination. In one group of patients the disease was limited to the prostate and this
group of patients had a 71 % and 41 % survival rate at
five and ten years respectively. In the other group of
patients the disease had extracapsular extension and
this group of patients had 41 % and 31 % survival rates
at five and ten years respectively. Hillaris and his
colleagues 4 from Memorial Hospital have reported
that all patients with intracapsular disease"Tf 1, T 2 ,
and Ts) and negative lymph nodes were alive and free
of disease at five years while disease-free survival
decreased to 70% in patients with extracapsular disease and negative nodes or in patients with intracapsular disease with positive nodes. Only 50% of
patients with extensive local disease (Ts and T 4 ) and
positive nodes were alive without evidence of disease
at five years. It has been my experience that dissemination of disease is more frequent in patients with a
large primary tumor, with a high-grade tumor, and in
the presence of histologically positive lymph nodes.
In addition, there is rapid systemic dissemination of
the disease once the para-aortic lymph nodes are
involved.
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Present Area of Clinical Investigation

The major cause of failure of definitive radiotherapy in carcinoma of the prostate is the spread of
tumor, outside the high dose of radiation field, either
to the lymph nodes or to the bones. It is generally
accepted that young patients (below 65 years), patients with a high-grade tumor and with diffuse involvement of the prostate gland (multiple chips involved, post-transurethral resection of the prostate)
have a poor survival rate even when they present with
early (stage A) disease. It remains to be seen whether
definitive radiation therapy in this select group of
patients with stage A carcinoma of the prostate will
alter the natural history and provide an improved
survival rate.
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